Related Experiment Video
Updated: May 17, 2025
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based
Johnna Perdrizet1, Emmanuelle Blanc2, Jessica Y El Khoury2
1Pfizer Canada, Kirkland, Quebec, Canada.
Insights
Delaying the introduction of pneumococcal conjugate vaccine 20 (PCV20) in France could lead to thousands of preventable pneumococcal disease cases and deaths. Early PCV20 implementation offers significant public health and economic benefits.
Area of Science:
- Public Health
- Epidemiology
- Health Economics
Background:
- Pneumococcal conjugate vaccines (PCVs) are crucial for preventing invasive pneumococcal disease (IPD) in infants.
- France currently uses PCV13 and PCV15, with potential for PCV20 introduction.
Purpose of the Study:
- To evaluate the public health and economic consequences of delaying PCV20 implementation in French infants.
- Comparison between delaying PCV20 versus continuous use of PCV15 and PCV13.
Main Methods:
- A population-based Markov model was adapted for the French pediatric population.
- Outcomes assessed included pneumococcal disease cases, deaths, and direct healthcare costs.
- The impact of a two-year PCV20 implementation delay was analyzed over time.
Main Results:
- A two-year delay in PCV20 implementation was projected to cause 15,356 additional pneumococcal disease cases and 1,489 deaths.
- This delay was associated with an estimated economic cost of €117.4 million compared to continuous PCV15 use.
- Similar trends, though slightly reduced, were observed when comparing PCV20 to PCV13.
Conclusions:
- Rapid implementation of PCV20 is estimated to prevent thousands of pneumococcal disease cases and deaths within two years.
- This timely introduction would mitigate substantial negative impacts on public health.
- Early adoption of PCV20 would also prevent considerable waste of healthcare resources.
Objectives:
We assessed the public health and economic impacts in France for infants below 1-year of delaying PCV20 (3 + 1) implementation compared to continuous use of PCV15 (2 + 1) and PCV13 (2 + 1).
Patients And Methods:
Population-based Markov model was adapted for French pediatric population. Outcomes included pneumococcal disease cases, deaths, and direct costs. Impact of a PCV20 two-year implementation delay was reported by month, quarter, and year.
Results:
Delaying PCV20 implementation in French children was estimated to result in preventable 15,356 disease cases and 1,489 deaths over two years, with cost of €117.4 million, versus the continuous use of PCV15. PCV20 versus PCV13 results were slightly reduced but followed a similar trend.
Conclusions:
Rapid implementation of PCV20 is estimated to prevent thousands of cases and deaths over two years compared to the continuous PCV15 or PCV13 use, reducing significant negative impact to public health outcomes and waste of health care resources.
